Cue Biopharma to Host Investor Call
June 07 2023 - 8:00AM
Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage
biopharmaceutical company developing a novel class of injectable
biologics to selectively engage and modulate disease-specific T
cells directly within the patient’s body, announced today that it
will host an investor call on Wednesday, June 14, 2023.
During the call, the company will provide an
overview and update on the clinical progress to date describing the
associated data presented at the 2023 American Society of Clinical
Oncology (ASCO) Annual Meeting on the company’s ongoing Phase 1
trials evaluating CUE-101, its lead clinical drug candidate from
the interleukin 2 (IL-2)-based CUE-100 series for the treatment of
patients with human papilloma virus (HPV16+) recurrent/metastatic
head and neck squamous cell carcinoma (R/M HNSCC) as monotherapy
and in combination with pembrolizumab (KEYTRUDA®). In addition, the
Company will provide a summary update on the second clinical drug
candidate from the IL-2-based CUE-100 series, CUE-102, being
evaluated in a Phase 1 monotherapy dose escalation and expansion
trial in patients with Wilms Tumor 1 (WT1)-positive
recurrent/metastatic solid cancers, as well as CUE-401, a
bispecific protein designed to induce and expand regulatory T cells
(Tregs) for the treatment of autoimmune and inflammatory diseases
partnered with Ono Pharmaceutical.
Webcast DetailsWednesday, June
14 at 4:30 p.m. EDT
Investors: |
1-877-407-9208 |
International: |
1-201-493-6784 |
Conference
ID: |
13739058 |
Request a return call via
the Call me™ link: |
https://callme.viavid.com/viavid/?callme=true&passcode=13736864&h=true&info=company-email&r=true&B=6 |
|
Participants can use guest
dial-in numbers above and be answered by an operator OR click the
Call me™ link for instant telephone access to the event. Call me™
link will be active 15 minutes prior to the scheduled start
time. |
Webcast: |
https://viavid.webcasts.com/starthere.jsp?ei=1617489&tp_key=9eb3faa313 |
A live and archived webcast of the presentation
will be available in the Investor and Media section of the
Company’s website at www.cuebiopharma.com. The webcast will be
archived for 30 days.
About the CUE-100
Series The CUE-100 series consists of Fc-fusion
biologics that incorporate peptide-MHC (pMHC) molecules along with
rationally engineered IL-2 molecules. This singular biologic is
anticipated to selectively target, activate and expand a robust
repertoire of tumor-specific T cells directly in the patient’s
body. The binding affinity of IL-2 for its receptor has been
deliberately attenuated to achieve preferential selective
activation of tumor-specific effector T cells while reducing the
potential for effects on regulatory T cells (Tregs) or broad
systemic activation, potentially mitigating the dose-limiting
toxicities associated with current IL-2-based therapies.
About Cue BiopharmaCue
Biopharma, a clinical-stage biopharmaceutical company, is
developing a novel class of injectable biologics to selectively
engage and modulate disease-specific T cells directly within the
patient’s body. The company’s proprietary platform,
Immuno-STAT™ (Selective Targeting and Alteration of T
cells) and biologics are designed to harness the body’s
intrinsic immune system as T cell engagers without the need for ex
vivo manipulation or broad systemic modulation.
Headquartered
in Boston, Massachusetts, we are led by an experienced
management team and independent Board of Directors with deep
expertise in immunology and immuno-oncology as well as the design
and clinical development of protein biologics.For more information
please visit www.cuebiopharma.com and follow us on
Twitter at https://twitter.com/CueBiopharma.Investor
ContactMarie CampinellSenior Director, Corporate
CommunicationsCue Biopharma,
Inc.mcampinell@cuebio.com Media ContactMaya
RomanchukLifeSci Communicationsmromanchuk@lifescicomms.com
Cue Biopharma (NASDAQ:CUE)
Historical Stock Chart
From Apr 2024 to May 2024
Cue Biopharma (NASDAQ:CUE)
Historical Stock Chart
From May 2023 to May 2024